PENK
Proenkephalin-A
Protein Summary
Met- and Leu-enkephalins compete with and mimic the effects of opiate drugs. They play a role in a number of physiologic functions, including pain perception and responses to stress. PENK(114-133) and PENK(237-258) increase glutamate release in the striatum. PENK(114-133) decreases GABA concentration in the striatum. This gene encodes a preproprotein that is proteolytically processed to generate multiple protein products. These products include the pentapeptide opioids Met-enkephalin and Leu-enkephalin, which are stored in synaptic vesicles, then released into the synapse where they bind to mu- and delta-opioid receptors to modulate the perception of pain. Other non-opioid cleavage products may function in distinct biological activities. [provided by RefSeq, Jul 2015]
- ENST00000314922
- ENSP00000324248
- ENSG00000181195
- ENST00000451791
- ENSP00000400894
- PE
- PENK-A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.92 | ||
PubMedID | 0.79 | ||
disease perturbation | 0.68 | ||
transcription factor perturbation | 0.68 | ||
transcription factor binding site profile | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1320.41 (req: < 5)
Gene RIFs: 37 (req: <= 3)
Antibodies: 366 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1320.41 (req: >= 5)
Gene RIFs: 37 (req: > 3)
Antibodies: 366 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 32
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0